Novomer, Inc.

Novomer and Penford Enter into Joint Development Agreement

Novomer and Penford Enter into Joint Development Agreement

January 17, 2012

Boston, Mass. – January 17, 2012 – Novomer Inc., a new materials company pioneering a family of high-performance plastics and polymers using renewable feedstocks such as carbon dioxide, and Penford Corporation, a company with significant business and expertise in specialty starches and sustainable bio-products  announce that they have entered into a Joint Development Agreement that will leverage the two companies’ core technologies and expertise.

AeroDesigns Inc.

Breathable Foods® Announces the Retail Launch of AeroShot Pure Energy™

Breathable Foods® Announces the Retail Launch of AeroShot Pure Energy™

January 17, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Breathable Foods announces the official launch of AeroShot Pure Energy in Boston and New York where it is now available to purchase in retail outlets. AeroShot is a first-of-its-kind, calorie-free breathable energy product that delivers an airborne shot of caffeine through a pocket-sized, single-use device. Offering consumers a unique way to get their caffeine, as little or as much as they need when they need it, this innovative supplement is revolutionizing the way people energize their lives.

Joule Unlimited, Inc.

JOULE SECURES $70M IN PRIVATE EQUITY INVESTMENTS FOR GROWTH

JOULE SECURES $70M IN PRIVATE EQUITY INVESTMENTS FOR GROWTH

January 17, 2012

WORLD FUTURE ENERGY SUMMIT – Abu Dhabi, UAE – January 17, 2012 – Joule today announced the closing of a $70 million third round of funding, supporting its aggressive timeline to commercialization and bringing its total to $110+ million raised to date. The round included investments from both new and prior undisclosed institutional and private sources that joined Flagship Ventures, Joule’s founding venture capital investor. The news was released in conjunction with Joule’s participation at the World Future Energy Summit, where President and CEO William J.

‘Beating heart’ transplants could boost success rate

‘Beating heart’ transplants could boost success rate

January 11, 2012

Amy DeStefano was a single mother juggling family life and a full-time job three winters ago when she caught what at first was just a persistent February cold. Then it spiraled into pneumonia and spread to her heart.
 
By last January, DeStefano, at 39, was on the waiting list for a heart transplant at Massachusetts General Hospital.
 
Her wait ended late last month when the social worker from Portsmouth, N.H., became the first patient in New England to receive an experimental “beating heart’’ transplant.

Receptos, Inc.

Receptos Achieves Milestone Under License of G-Protein Coupled Receptor Crystal Structure Determination Technology

Receptos Achieves Milestone Under License of G-Protein Coupled Receptor Crystal Structure Determination Technology

January 10, 2012

SAN DIEGO, Jan. 10, 2012 -- Receptos Inc. today announced the successful achievement of the technology transfer milestone under its license and technology transfer deal with Janssen Pharmaceuticals, Inc. (formerly Ortho-McNeil Janssen Pharmaceuticals, Inc.), for Receptos' breakthrough GPCR crystal structure determination technology.

FLAGSHIP VENTURES CLOSES $270 MILLION EARLY-STAGE VENTURE CAPITAL FUND

FLAGSHIP VENTURES CLOSES $270 MILLION EARLY-STAGE VENTURE CAPITAL FUND

January 11, 2012

Cambridge, Mass. – Jan. 11, 2012 – Flagship Ventures, a leading venture capital firm focused on healthcare and sustainability, today announced the year-end 2011 close of its largest fund to date, raising $270 million for Flagship Ventures Fund IV L.P., exceeding its target of $250 million. Investors in Flagship Ventures Fund IV include pension funds, foundations, fund-of-funds, corporations and individuals. Joining prior fund investors were several new limited partners.

BG Medicine, Inc.

BG Medicine, Inc. Appoints Eric Bouvier as Chief Executive Officer

BG Medicine, Inc. Appoints Eric Bouvier as Chief Executive Officer

January 9, 2012

WALTHAM, Mass., Jan. 9, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that its Board of Directors has appointed Eric Bouvier, Ph.D., as the company's new President and Chief Executive Officer and a member of the Board of Directors, effective as of January 9, 2012.

Blend Therapeutics Founded by Leading Researchers in Chemistry and Nanomedicine to Develop a New Class of Integrative Combination Medicines

Blend Therapeutics Founded by Leading Researchers in Chemistry and Nanomedicine to Develop a New Class of Integrative Combination Medicines

January 6, 2012

WATERTOWN, Mass., Jan 06, 2012 (BUSINESS WIRE) -- Blend Therapeutics, a biotechnology company discovering and developing a new class of integrative combination medicines, announced the company's founding and strategic mission to develop innovative combination medicines with novel pharmacological profiles designed to target distinct disease pathways with optimal efficacy and safety.

Avedro, Inc.

Avedro Announces CE Approval for Lasik Xtra ™

Avedro Announces CE Approval for Lasik Xtra ™

January 4, 2012

Waltham, Massachusetts, USA, January 4, 2012 -- Avedro, Inc. announced today that the Company’s proprietary Lasik Xtra procedure has received CE Approval. Lasik Xtra is a two minute procedure used in conjunction with standard Lasik to restore the biomechanical integrity and strength to the cornea after a Lasik procedure. Lasik Xtra has been successfully used in thousands of Lasik surgeries outside the US.

Ensemble Therapeutics Corporation

Ensemble Therapeutics Advances Macrocycle IL-17 Antagonist Program: Reports First Known Small Molecule Inhibitors of Important Autoimmune Target

Ensemble Therapeutics Advances Macrocycle IL-17 Antagonist Program: Reports First Known Small Molecule Inhibitors of Important Autoimmune Target

January 5, 2012

CAMBRIDGE, MA – January 5, 2012 -- Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today that the company has identified a series of unique small molecule antagonists of Interleukin-17, a pro-inflammatory cytokine implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn’s and intestinal bowel disease.